What Has Been the Progress and Growth of the Oral Solid Dosage Contract Manufacturing Market in Recent Years?
The oral solid dosage contract manufacturing market has seen considerable growth due to a variety of factors.
• The oral solid dosage contract manufacturing market has grown significantly. It is projected to grow from $39.39 billion in 2024 to $42.51 billion in 2025, at a compound annual growth rate (CAGR) of 7.9%.
Growth factors include a growing global population, the rising incidence of chronic diseases, and a stronger focus on research and development.
What Can Be Expected from the Oral Solid Dosage Contract Manufacturing Market Size?
The oral solid dosage contract manufacturing market is expected to maintain its strong growth trajectory in upcoming years.
• The oral solid dosage contract manufacturing market is expected to grow to $56.89 billion by 2029, at a CAGR of 7.6%.
This growth is driven by increasing outsourcing in the pharmaceutical industry, advancements in drug delivery technologies, and growing drug development activities. Key trends include innovations in drug delivery technology, 3D printing integration, and advancements in controlled-release technologies.
What Are the Critical Driver Fuelling The Oral Solid Dosage Contract Manufacturing Market's Growth?
The surge in generic drugs' demand is projected to spur the expansion of the oral solid dosage contract manufacturing industry. Generic medications are drugs that have the same bioequivalence as branded medicines in terms of dosage, potency, safety, functionality, quality, and intended application. The augmented demand for generic drugs stems from patent terminations, cost-reduction initiatives, regulatory stimulants, and broader healthcare access. Oral solid dosage contract manufacturing significantly contributes to the creation and dispersion of generic drugs through capitalizing on contract producers' skills to improve their operational productivity, minimize expenses, ensure superior quality production, and bring their products to the market quickly and effectively. For example, the Food and Drug Administration, a federal agency based in the US, reported in 2022 that an estimated 91% of all prescriptions in the USA were issued with generic drugs, with over 32,000 generic drugs receiving FDA approval. Therefore, the need for generic medications fuels the expansion of the oral solid dosage contract manufacturing industry.
How Is The Oral Solid Dosage Contract Manufacturing Market segmented?
The oral solid dosage contract manufacturing market covered in this report is segmented –
1) By Product Type: Tablets, Capsules, Powders, Granules, Other Product Types
2) By Service: Drug Product Development, Fill Finish Product Manufacturing, API Manufacturing, Packaging And Labelling, Other Applications
3) By Therapeutic Area: Oncology, Cardiovascular Diseases, Metabolic Disorders, Neurological Disorders, infectious Diseases, Gastrointestinal Diseases, Other Therapeutic Areas
4) By End User: Large Size Companies, Medium And Small Size Companies
Subsegments:
1) By Tablets: Compressed Tablets, Effervescent Tablets, Chewable Tablets, Coated Tablets (Enteric, Film Coated), Sustained Or Controlled Release Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gel Capsules, Vegetarian Capsules, Liquid-Filled Capsules, Delayed Release Capsules
3) By Powders: Powders For Oral Suspension, Powders For Direct Compression, Powders For Mixing Or Blending, Instant Dissolving Powders
4) By Granules: Granules For Direct Compression, Granules For Tabletting, Effervescent Granules, Delayed Or Controlled Release Granules
5) By Other Product Types: Lozenges, Oral Strips, Oral Thin Films, Effervescent Tablets Or Granules
Pre-Book The Oral Solid Dosage Contract Manufacturing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Oral Solid Dosage Contract Manufacturing Market?
Key players in the oral solid dosage contract manufacturing market are concentrating their efforts on creating ground-breaking solutions like continuous manufacturing lines, to maintain their competitive edge. A continuous manufacturing line is a production setup or system leveraging continuous manufacturing techniques to fabricate pharmaceuticals or other commodities. For instance, WuXi STA, a pharmaceutical corporation based in China, embarked on its maiden continuous manufacturing line for oral solid pharmaceutical formulations in January 2023. This state-of-the-art facility signifies a considerable progress in pharmaceutical production, applying continuous manufacturing principles to boost efficiency, quality, and adaptability in drug manufacturing procedures. This nimbleness expedites production schedules and minimizes downtime, ultimately facilitating a quicker distribution of crucial medications to patients.
Who Are the Key Players In The Oral Solid Dosage Contract Manufacturing Market?
Major companies operating in the oral solid dosage contract manufacturing market are:
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Amgen Inc.
• Merck KGaA
• Siemens Healthineers AG
• Evonik Industries AG
• Teva Pharmaceutical Industries Ltd.
• Lonza Group AG
• Catalent Inc.
• Patheon Pharma Services
• Fareva Holding SA
• Piramal Enterprises Limited
• Hetero Drugs Limited
• Siegfried Holding AG
• Recipharm AB
• Almac Group Limited
• Aenova Holding GmbH
• Jubilant Pharmova Limited
• Cambrex Corporation
• International Chemical Investors Group (ICIG) operates under the CordenPharma brand
• Ajinomoto Co. Inc.
• Hovione Holding Ltd.
• Alcami Corporation
What Is The Most Dominant Region In The Oral Solid Dosage Contract Manufacturing Market?
Asia-Pacific was the largest region in the oral solid dosage contract manufacturing market in 2023. The regions covered in the oral solid dosage contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
